ReportLinker<\/p>\n
Abstract: What`s New for 2022? -Global competitiveness and key competitor percentage market shares. -Market presence across multiple geographies - Strong\/Active\/Niche\/Trivial.<\/p>\n
New York, March 11, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report \"Global Gene Therapy Industry\" - https:\/\/www.reportlinker.com\/p05817594\/?utm_source=GNW<\/a> -Online interactive peer-to-peer collaborative bespoke updates -Access to our digital archives and MarketGlass Research Platform -Complimentary updates for one year<\/p>\n Global Gene Therapy Market to Reach US$3.4 Billion by the Year 2027 <\/p>\n Amid the COVID-19 crisis, the global market for Gene Therapy estimated at US$970.5 Million in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at a CAGR of 19.5% over the period 2020-2027.Viral, one of the segments analyzed in the report, is projected to grow at a 19.7% CAGR to reach US$3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Viral segment is readjusted to a revised 17.6% CAGR for the next 7-year period. This segment currently accounts for a 11.1% share of the global Gene Therapy market. <\/p>\n The U.S. Accounts for Over 53.7% of Global Market Size in 2020, While China is Forecast to Grow at a 25.1% CAGR for the Period of 2020-2027 <\/p>\n The Gene Therapy market in the U.S. is estimated at US$521.3 Million in the year 2020. The country currently accounts for a 53.71% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$107.9 Million in the year 2027 trailing a CAGR of 25.1% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.3% and 18.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 18.6% CAGR while Rest of European market (as defined in the study) will reach US$107.9 Million by the year 2027.Select Competitors (Total 154 Featured) - <\/p>\n Story continues<\/p>\n Abeona Therapeutics Inc.<\/p>\n Adaptimmune Therapeutics Plc<\/p>\n Advantagene, Inc.<\/p>\n Adverum Biotechnologies, Inc<\/p>\n Akcea Therapeutics<\/p>\n Alnylam Pharmaceuticals, Inc.<\/p>\n Amgen Inc<\/p>\n Anchiano Therapeutics, Inc.<\/p>\n AnGes, Inc.<\/p>\n Applied Genetic Technologies Corporation<\/p>\n Audentes Therapeutics, Inc.<\/p>\n Biogen<\/p>\n bluebird bio, Inc.<\/p>\n Chiesi Farmaceutici S.p.A<\/p>\n CRISPR Therapeutics AG<\/p>\n Editas Medicine, Inc.<\/p>\n Gilead Sciences, Inc.<\/p>\n Intellia Therapeutics, Inc.<\/p>\n Jazz Pharmaceuticals, plc.<\/p>\n Juno Therapeutics, Inc<\/p>\n Merck KGaA<\/p>\n MolMed S.p.A.<\/p>\n Novartis Gene Therapies<\/p>\n Orchard Therapeutics plc<\/p>\n REGENXBIO Inc.<\/p>\n Sangamo Therapeutics, Inc.<\/p>\n Sarepta Therapeutics, Inc.<\/p>\n Sibiono GeneTech Co. Ltd.<\/p>\n Spark Therapeutics, Inc.<\/p>\n uniQure N.V.<\/p>\n Voyager Therapeutics<\/p>\n Read the full report: https:\/\/www.reportlinker.com\/p05817594\/?utm_source=GNW<\/a> <\/p>\n I. METHODOLOGY <\/p>\n II. EXECUTIVE SUMMARY <\/p>\n 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession A Prelude to Gene Therapy Classification of Gene Therapies COVID-19 Causes Gene Therapy Market to Buckle & Collapse COVID-19 Impact on Different Aspects of Gene Therapy Manufacturing & Delivery Research & Clinical Development Commercial Operations & Access Managing Derailed Operations Focus on Clinical Development Programs Targeting Manufacturing & Delivery Strategies Securing Supplies Remote Working Gene Therapy Set to Witness Rapid Growth Post COVID-19 Gene Therapy - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong\/Active\/Niche\/Trivial for Players Worldwide in 2022 (E) By Vector Type VIRAL VECTORS ACCOUNT FOR A MAJOR SHARE OF THE MARKET Adeno-Associated Virus Vectors Lentivirus NON-VIRAL VECTORS TO WITNESS FASTER GROWTH US and Europe Dominate the Gene Therapy Market Oncology Represents the Largest Indication for Gene Therapy Market Outlook WORLD BRANDS <\/p>\n 2. FOCUS ON SELECT PLAYERS Recent Market Activity Select Innovations <\/p>\n 3. MARKET TRENDS & DRIVERS Availability of Novel Therapies Drive Market Growth Select Approved Gene Therapy Products Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy Lentiviral Vectors Witness Increasing Interest Rising Cancer Incidence Worldwide Spurs Demand for Gene Therapy Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018 Number of New Cancer Cases and Deaths (in Million) by Region for 2018 Compelling Level of Technology & Innovation to Ignite Gene Therapy Promising Gene Therapy Innovations for Treatment of Inherited Retinal Diseases Gene Therapy Pivots M&A Activity in Dynamic Domain of Genomic Medicine M&As Rampant in Gene Therapy Space Gene Therapy Deals: 2018 and 2019 Emphasis on Formulating Robust Regulatory Framework Strong Gene Therapy Pipeline Gene Therapy: Phase III Clinical Trials OHSU Implements First-Ever LCA10 Gene Therapy Clinical Trial with CRISPR Growing Funding for Gene Therapy Research Market Issues & Challenges <\/p>\n 4. GLOBAL MARKET PERSPECTIVE Table 1: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR <\/p>\n Table 2: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 3: World 10-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2017, 2021 & 2027 <\/p>\n Table 4: World Recent Past, Current & Future Analysis for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR <\/p>\n Table 5: World Historic Review for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 6: World 10-Year Perspective for Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2021 & 2027 <\/p>\n Table 7: World Recent Past, Current & Future Analysis for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR <\/p>\n Table 8: World Historic Review for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 9: World 10-Year Perspective for Non-Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2021 & 2027 <\/p>\n Table 10: World Recent Past, Current & Future Analysis for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR <\/p>\n Table 11: World Historic Review for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 12: World 10-Year Perspective for Oncological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2021 & 2027 <\/p>\n Table 13: World Recent Past, Current & Future Analysis for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR <\/p>\n Table 14: World Historic Review for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 15: World 10-Year Perspective for Rare Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2021 & 2027 <\/p>\n Table 16: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR <\/p>\n Table 17: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 18: World 10-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2021 & 2027 <\/p>\n Table 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR <\/p>\n Table 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 21: World 10-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2021 & 2027 <\/p>\n III. MARKET ANALYSIS <\/p>\n UNITED STATES Gene Therapy Market Presence - Strong\/Active\/Niche\/Trivial - Key Competitors in the United States for 2022 (E) Table 22: USA Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR <\/p>\n Table 23: USA Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 24: USA 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2021 & 2027 <\/p>\n Table 25: USA Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR <\/p>\n Table 26: USA Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 27: USA 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2021 & 2027 <\/p>\n CANADA Table 28: Canada Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR <\/p>\n Table 29: Canada Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 30: Canada 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2021 & 2027 <\/p>\n Table 31: Canada Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR <\/p>\n Table 32: Canada Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 33: Canada 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2021 & 2027 <\/p>\n JAPAN Gene Therapy Market Presence - Strong\/Active\/Niche\/Trivial - Key Competitors in Japan for 2022 (E) Table 34: Japan Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR <\/p>\n Table 35: Japan Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 36: Japan 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2021 & 2027 <\/p>\n Table 37: Japan Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR <\/p>\n Table 38: Japan Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 39: Japan 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2021 & 2027 <\/p>\n CHINA Gene Therapy Market Presence - Strong\/Active\/Niche\/Trivial - Key Competitors in China for 2022 (E) Table 40: China Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR <\/p>\n Table 41: China Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 42: China 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2021 & 2027 <\/p>\n Table 43: China Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR <\/p>\n Table 44: China Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 45: China 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2021 & 2027 <\/p>\n EUROPE Gene Therapy Market Presence - Strong\/Active\/Niche\/Trivial - Key Competitors in Europe for 2022 (E) Table 46: Europe Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR <\/p>\n Table 47: Europe Historic Review for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 48: Europe 10-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2017, 2021 & 2027 <\/p>\n Table 49: Europe Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR <\/p>\n Table 50: Europe Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 51: Europe 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2021 & 2027 <\/p>\n Table 52: Europe Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR <\/p>\n Table 53: Europe Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 and % CAGR <\/p>\n Table 54: Europe 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2021 & 2027 <\/p>\n <\/p>\n See the article here: ReportLinker Abstract: What`s New for 2022? -Global competitiveness and key competitor percentage market shares Continue reading
\nGlobal Gene Therapy Market to Reach US$3.4 Billion by the Year 2027 - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"